PCSK9 antagonists

An aqueous formulation comprising:

• about 1 mg/ml to about 200 mg/ml of an antagonist antibody that specifically binds to PCSK9 comprising amino acid sequence of SEQ ID NO:
• 188;
• about 1 mM to about 100 mM of a buffer;
• about 0.01 mg/ml to about 10 mg/ml of a surfactant;
• and
• about 100 mM to about 400 mM of a stabilizer;
• wherein the formulation has a pH at about 5.0 to about 6.5, and wherein the antibody comprises a heavy chain variable region (VH) complementary determining region one (CDR1) having the amino acid sequence shown in SEQ ID NO:8, 59, or 60, a VH CDR2 having the amino acid sequence shown in SEQ ID NO:61 or 9, a VH CDR3 having the amino acid sequence shown in SEQ ID NO:10, a light chain variable region (VL) CDR1 having the amino acid sequence shown in SEQ ID NO:11, a VL CDR2 having the amino acid sequence shown in SEQ ID NO:12, and a VL CDR3 having the amino acid sequence shown in SEQ ID NO:13.

An aqueous formulation comprising:

• about 1 mg/ml to about 200 mg/ml of an antagonist antibody that specifically binds to PCSK9 comprising amino acid sequence of SEQ ID NO:
• 188;
• about 1 mM to about 100 mM of a buffer;
• about 0.01 mg/ml to about 10 mg/ml of a surfactant;
• about 100 mM to about 400 mM of a stabilizer;
• and
• about 0.01 mM to about 1.0 mM of a chelating agent;
• wherein the formulation has a pH at about 5.0 to about 6.5, and wherein the antibody comprises a heavy chain variable region (VH) complementary determining region one (CDR1) having the amino acid sequence shown in SEQ ID NO:8, 59, or 60, a VH CDR2 having the amino acid sequence shown in SEQ ID NO:61 or 9, a VH CDR3 having the amino acid sequence shown in SEQ ID NO:10, a light chain variable region (VL) CDR1 having the amino acid sequence shown in SEQ ID NO:11, a VL CDR2 having the amino acid sequence shown in SEQ ID NO:12, and a VL CDR3 having the amino acid sequence shown in SEQ ID NO:13.